Cannula Market

Cannula Market Forecast and Outlook by Fact.MR

• In 2025, the cannula market was valued at USD 224.6 million.
• Based on Fact.MR analysis, demand for cannulas is estimated to grow to USD 239.0 million in 2026 and USD 444.4 million by 2036.
• FACT.MR projects a CAGR of 5.6% during the forecast period.

Summary of the Cannula Market

• Market Definition
  • The market covers nasal, IV, cardiac, aesthetic, and other cannula devices supplied in sterile disposable and reusable formats to hospitals, clinics, ASCs, and home healthcare providers globally.
• Demand Drivers
  • Surgical procedure volumes are rising across aging populations in developed markets, increasing per-hospital IV and cardiac cannula consumption in planned and emergency care settings.
  • Home healthcare adoption is expanding nasal cannula demand beyond institutional settings, driven by rising COPD prevalence and post-acute oxygen therapy discharge programs in the United States and Western Europe.
  • Aesthetic procedure growth in dermatology clinics and medspas is sustaining blunt-tip aesthetic cannula demand, particularly among practitioners performing filler injection protocols that prioritize patient safety and bruising reduction.
• Key Segments Analyzed
  • By Product Type: IV Cannula holds approximately 50% share in 2026, reflecting its universal use in hospital fluid and drug delivery workflows across surgical, emergency, and chronic care settings.
  • By Material Type: Plastic (PVC, Polyurethane) accounts for approximately 70% share in 2026, underpinned by cost efficiency, regulatory acceptance, and compatibility with high-volume disposable manufacturing.
  • By Application: Fluid/Drug Delivery holds approximately 45% share in 2026, anchored by IV cannula use in medication administration, chemotherapy delivery, and saline infusion across inpatient settings.
  • By End User: Hospitals account for approximately 60% share in 2026, driven by high procedural throughput and infection control mandates requiring sterile single-use cannula procurement at scale.
  • By Usage Type: Disposable Cannulas account for approximately 80% share in 2026, reflecting hospital policy shifts toward single-use devices under infection prevention guidelines and regulatory sterilization standards.
• Analyst Opinion at FACT.MR
  • Shambhu Nath Jha, Principal Analyst at Fact.MR, opines, ‘CXOs should note that volume growth is increasingly concentrated among suppliers with pre-approved vendor status in major hospital group tenders. Procurement consolidation is tightening across regulated markets. Entry barriers are rising for new participants. Competitive access is becoming limited to established, compliant suppliers.
• Strategic Implications
  • Pursue pre-qualification under hospital group and government tender panels in India and China to establish supply continuity before procedural volume growth intensifies competition for approved vendor slots.
  • Expand disposable cannula product lines validated for ASC and home healthcare settings to capture the fastest-growing end user segments outside of the hospital channel.
  • Invest in material innovation for medical-grade silicone and polyurethane cannula variants to address premium pricing opportunities in aesthetic procedures and cardiac surgery, where material comfort and biocompatibility command higher average selling prices.
• Methodology
  • Market sizing based on unit shipment volumes, average selling prices by product type, and procedural volume benchmarks. Validated with 2024 to 2025 hospital procurement and distributor data.
  • Supported by FDA 510(k) clearance records, CE marking databases, hospital tender outcomes, and company investor disclosures from Becton Dickinson, Teleflex, and Medtronic.
  • Forecasts incorporate surgical volume projections, home healthcare expansion data, infection control policy trends, and aesthetic procedure growth rates across Asia Pacific and North America.

The market is set to generate USD 205.4 million in incremental revenue over the forecast period. Growth remains structurally steady. It is driven by rising procedural volumes across surgical, respiratory, and aesthetic care. Demand is consistent across both acute and chronic care settings.

Raw material costs are increasing. Medical-grade PVC and silicone are becoming more expensive. This is creating moderate margin pressure. Disposable cannula manufacturers are more exposed, especially in public hospital tenders. Pricing sensitivity remains a key constraint.

Procurement trends are shifting toward sterile, pre-validated disposable formats. Infection control protocols are becoming stricter. Hospitals are limiting the use of reusable cannulas in invasive procedures. Becton, Dickinson and Company and Teleflex Incorporated are aligning with this shift. Both are focusing on single-use IV and nasal cannula systems.

Growth varies across key countries. India leads with 7.2% CAGR through 2036. Expansion is supported by healthcare infrastructure and large patient volumes. China follows at 6.9%, driven by hospital capacity growth. Brazil records 6.5%, supported by private sector expansion. The United States grows at 6.0%, led by chronic care and surgical demand. Germany reaches 5.8%, with stable clinical demand. Japan posts 5.6%, supported by aging population care needs.

Segmental Analysis

Cannula Market Analysis by Product Type

Based on FACT.MR, IV Cannula holds approximately 50% share in 2026. IV cannulas are the foundational vascular access device across inpatient settings, required for every hospitalized patient receiving fluids or parenteral medications.

• Becton Dickinson IV Portfolio Expansion: Becton, Dickinson and Company expanded its BD Nexiva Closed IV Catheter System distribution to additional Asia Pacific markets in Q3 2024, targeting hospital infection control procurement in India and Southeast Asia where IV cannula adoption is growing rapidly. [5]
• Teleflex Nasal Cannula Development: Teleflex Incorporated launched an updated high-flow nasal cannula design for adult ICU and COPD management in Q1 2025, incorporating reduced-friction material and improved fixation to support extended oxygen therapy wear times in home healthcare settings. [1]
• Aesthetic Cannula Procedure Growth: The American Society of Plastic Surgeons reported that hyaluronic acid filler procedures, the primary application for blunt-tip aesthetic cannulas, grew 8% in 2024 in the United States, confirming sustained expansion of the aesthetic cannula sub-segment outside hospital procurement. [4]

Cannula Market Analysis by Material Type

Based on FACT.MR, Plastic (PVC, Polyurethane) holds approximately 70% share in 2026. Plastic cannulas dominate because of their combination of regulatory acceptance, manufacturing cost efficiency, and compatibility with single-use sterile production at high volumes.

• Nipro Corporation PVC Cannula Investment: Nipro Corporation expanded its medical-grade PVC IV cannula production capacity at its Indian manufacturing facility in 2024, targeting government hospital tender supply under the PM-JAY scheme and broader public health procurement programs. [6]
• Silicone Material Technology Development: Medtronic plc filed regulatory submissions in 2024 for updated silicone-body cardiac cannula designs with enhanced flexibility profiles for minimally invasive cardiac surgery, reflecting ongoing material innovation in the premium surgical cannula segment. [7]
• PVC Supply Chain Trend: Medical-grade PVC pricing increased approximately 6% in 2024 due to petrochemical feedstock cost pressures, introducing margin compression for high-volume disposable IV cannula manufacturers dependent on commodity plastic supply. [8]

Cannula Market Analysis by Application

Based on FACT.MR, Fluid/Drug Delivery holds approximately 45% share in 2026. This application anchors demand through the universal requirement for IV access in inpatient medication administration, chemotherapy, and saline infusion.

• Vygon Group Fluid Delivery Portfolio: Vygon Group expanded its IV cannula range for neonatal and paediatric fluid delivery applications in 2024, launching micro-bore cannula variants for low-volume drug administration in specialist hospital settings across France and Germany. [9]
• Home Oxygen Therapy Adoption: The U.S. Centers for Medicare and Medicaid Services reported in 2024 that home oxygen therapy equipment claims, including nasal cannula supplies, grew 9% year-over-year as post-acute care discharge programs expanded COPD patient management outside hospital walls.
• Surgical Procedure Volume Trend: The American Hospital Association reported that inpatient surgical procedure volumes at U.S. hospitals recovered to pre-pandemic baselines and grew 4% in 2024, directly increasing cardiac and general surgery cannula demand across major hospital systems.

Cannula Market Analysis by End User

Based on FACT.MR, Hospitals hold approximately 60% share in 2026. Hospital procurement dominates because every inpatient encounter involving fluid delivery, oxygen therapy, or surgery requires cannula supply at the individual patient level..

• ConvaTec Group Hospital Supply Agreement: ConvaTec Group plc announced multi-year cannula and vascular access device supply agreements with major UK National Health Service hospital trusts in Q4 2024, securing institutional supply channels for its single-use IV cannula product lines.
• ASC Procedure Migration Trend: The Ambulatory Surgery Center Association reported that ASC-based surgical procedure volumes in the United States grew 7% in 2024, with cardiology and orthopedic procedures migrating from inpatient settings, driving corresponding disposable cannula demand in outpatient surgical facilities.
• Home Healthcare Channel Expansion: Smiths Medical expanded its home infusion and nasal cannula product distribution in 2024 through agreements with regional home health equipment distributors in the United States, targeting post-discharge oxygen therapy and outpatient infusion therapy patients.

Cannula Market Analysis by Usage Type

Based on FACT.MR, Disposable Cannulas hold approximately 80% share in 2026. Single-use cannulas dominate because infection control policies across hospital systems in North America, Europe, and Asia Pacific are increasingly prohibiting or restricting reprocessing of devices originally labeled for single use.

• Becton Dickinson Single-Use Compliance Push: Becton, Dickinson and Company issued updated single-use labeling and clinical guidance for its IV cannula product lines in 2024, aligning documentation with FDA single-use device enforcement priorities and hospital accreditation infection control standards.
• Reusable Cannula Regulatory Restrictions: The U.S. FDA published updated enforcement discretion guidance on single-use device reprocessing in 2024, narrowing permissible reprocessing categories and applying heightened pre-market requirements for reprocessors of cannulas and vascular access devices.
• Disposable Supply Chain Scaling: Nipro Corporation and Vygon Group both expanded disposable cannula manufacturing capacity in 2024 and early 2025, citing hospital procurement contract growth and anticipated volume increases from government tender programs in India, Brazil, and Southeast Asia as primary investment drivers.

Drivers, Restraints, and Opportunities

FACT.MR analysts view the cannula market as structurally stable and procedure-driven. Growth is linked to clinical and surgical volumes. It is not dependent on discretionary spending. IV cannulas anchor demand due to their essential role in fluid and drug delivery.

The market is shifting toward disposable usage. Reusable cannula procurement is declining in regulated settings. Infection control policies are becoming stricter. Hospitals are moving to single-use formats. Price premiums for disposables are accepted. This is due to high liability risks from infection events.

• Single-Use Regulatory Mandates: The U.S. Food and Drug Administration strengthened guidance in 2024. Reprocessed single-use cannulas face strict scrutiny. Non-compliant facilities risk penalties and exclusion. This is accelerating adoption of disposable-only procurement models. [2]
• India Healthcare Expansion: Government of India expanded coverage under Ayushman Bharat PM-JAY. Over 550 million beneficiaries are covered. Hospital procedures increased by 14% in FY2024–25. Each procedure requires disposable IV cannulas. Nineteen new medical colleges were approved in 2024. This adds new procurement demand. [3]
• Aesthetic Cannula Growth: American Society of Plastic Surgeons reported 8% growth in 2024. Minimally invasive procedures are increasing. Blunt-tip cannulas are widely used in fillers. Demand is rising in dermatology and aesthetics. This adds a new growth layer beyond hospitals. [4]

Regional Analysis

The cannula market is assessed across Asia Pacific, North America, Europe, Latin America, and Middle East and Africa, covering 40+ countries across distinct hospital procurement models, infection control regulatory frameworks, and surgical procedure volume trajectories. The full report offers market attractiveness analysis by region and country.

Source: Fact.MR (FACT.MR) analysis, based on proprietary forecasting model and primary research

Asia Pacific Cannula Market Analysis

Asia Pacific continues to outpace other regions in cannula demand growth. India and China act as the core expansion hubs. Growth is supported by large-scale healthcare access programs and rising procedural volumes.

• India: A policy-led expansion defines India’s cannula demand trajectory. Growth reaches 7.2% CAGR through 2036. Ayushman Bharat PM-JAY has scaled access to over 550 million beneficiaries. Covered procedures rose 14% in FY2024–25. Each procedure requires disposable IV cannulas. The Government of India approved 19 new medical colleges in 2024. These create fresh procurement pipelines. Demand growth is driven by institutional expansion rather than organic trends.

• China: Infrastructure-led capacity growth underpins China’s market expansion. The market grows at 6.9% CAGR through 2036. The National Health Commission of China approved 312 hospital projects in 2024. This directly expands procurement capacity. Becton, Dickinson and Company expanded BD Nexiva distribution in 2024. Demand is rising in newly commissioned hospitals. Tier-2 and Tier-3 cities are driving procedural growth.
• Japan: Demographics define Japan’s steady market expansion. Growth reaches 5.6% CAGR through 2036. The Ministry of Health, Labour and Welfare reported 29.1% elderly population in 2024. This sustains consistent demand. Respiratory and post-surgical care remain key segments. Nipro Corporation maintains strong domestic supply leadership. Long-term partnerships support stable procurement.

FACT.MR’s analysis of the cannula market in Asia Pacific includes India, China, Japan, South Korea, ASEAN, and Australia and New Zealand. Readers can find infrastructure investment data, procurement trends, and disposable adoption benchmarks.

North America Cannula Market Analysis

North America remains the largest revenue-generating region. The market is shaped by strict regulatory compliance and standardized procurement systems. The United States drives demand through advanced healthcare infrastructure and aging population needs. Becton, Dickinson and Company and Teleflex Incorporated dominate institutional supply.

• United States: A shift toward home-based care is reshaping cannula demand in the U.S. Growth stands at 6.0% CAGR through 2036. The Centers for Medicare & Medicaid Services reported a 9% rise in home oxygen therapy claims in 2024. This expands nasal cannula use beyond hospitals. The U.S. Food and Drug Administration tightened single-use enforcement in 2024. Systems like HCA Healthcare and Ascension Health are shifting to single-use procurement. Disposable demand is accelerating at scale.

FACT.MR’s analysis of the cannula market in North America includes the United States, Canada, and Mexico. Readers can find regulatory impacts, homecare demand trends, and procurement data.

Europe Cannula Market Analysis

Europe operates as a compliance-driven cannula market. Procurement is centralized and regulated under national health systems. CE marking and EU MDR create high entry barriers. ConvaTec Group plc, Vygon Group, and Smiths Medical hold established supply relationships.

• Germany: Regulatory tightening is shaping demand dynamics in Germany. Growth is 5.8% CAGR through 2036. The country maintains a large hospital base. The Federal Institute for Drugs and Medical Devices updated single-use guidance in 2024. Reprocessing restrictions are increasing. Hospitals are shifting toward disposable cannulas. Compliance is the primary demand driver.

FACT.MR’s analysis of the cannula market in Europe includes Germany, France, the UK, Italy, Spain, and Rest of Europe. Readers can find compliance benchmarks, reimbursement trends, and demand forecasts.

Latin America Cannula Market Analysis

Latin America is expanding steadily with rising healthcare investment. Private sector growth is a key driver. Brazil and Mexico lead regional demand. Public healthcare programs are also improving access. Nipro Corporation and Vygon Group are strengthening regional distribution.

• Brazil: Insurance-led expansion is driving cannula demand in Brazil. Growth is 6.5% CAGR through 2036. The Agência Nacional de Saúde Suplementar expanded coverage in 2024. This increased surgical volume. The ANVISA updated device registration rules. Entry pathways for suppliers are clearer. Procurement demand is rising across private hospitals.

FACT.MR’s analysis of the cannula market in Latin America includes Brazil, Argentina, Mexico, and Rest of Latin America. Readers can find private healthcare growth data, regulatory impacts, and procurement trends.

Competitive Aligners for Market Players

Competitive positioning in the cannula market is increasingly defined by regulatory alignment and procurement access. Suppliers that secure early approval within hospital tender systems gain a durable advantage. Large players such as Becton, Dickinson and Company and Teleflex Incorporated have built scale by aligning product portfolios with single-use compliance standards. This has allowed them to embed deeply within institutional purchasing frameworks.

A key competitive lever is the ability to deliver high-volume, sterile, disposable cannulas at consistent quality. As hospitals shift away from reusable devices, manufacturing scale and supply chain reliability become critical. Companies that can meet bulk procurement requirements without compromising regulatory standards are better positioned to win long-term contracts.

Geographic expansion is another important aligner. Markets such as India and China are driven by infrastructure growth and public healthcare programs. Establishing local manufacturing or distribution partnerships helps suppliers participate in government tenders and reduce cost pressures. Nipro Corporation has demonstrated this through strong regional integration.

Product innovation also plays a role, though it is incremental rather than disruptive. Improvements in safety features, ease of insertion, and patient comfort support differentiation. However, compliance and cost efficiency remain more decisive than feature upgrades. Pricing strategy must balance margin with competitiveness. Public hospital tenders are highly price-sensitive, while private healthcare systems allow some premium for validated, high-quality disposables. Players that optimize this balance across regions will sustain growth in an increasingly consolidated and regulation-driven market.

Key Players

• Becton, Dickinson and Company
• Teleflex Incorporated
• Medtronic plc
• Smiths Medical
• Vygon Group
• Boston Scientific Corporation
• Nipro Corporation
• ConvaTec Group plc

Bibliography

• [1] Teleflex Incorporated. (2024). Q3 2024 Earnings Call Transcript: Vascular Access Portfolio Strategy and High-Flow Nasal Cannula Product Development Update. Teleflex Investor Relations, November 2024. ir.teleflex.com
• [2] U.S. Food and Drug Administration. (2024). Enforcement Guidance Update: Single-Use Device Reprocessing Restrictions for Vascular Access and Cannula Products. FDA Medical Devices, 2024. fda.gov/medical-devices
• [3] Government of India, Ministry of Health and Family Welfare. (2024). Ayushman Bharat PM-JAY Annual Report FY2024–25: Beneficiary Coverage, Authorized Procedures, and New Government Medical College Approvals. National Health Authority, 2024. pmjay.gov.in
• [4] American Society of Plastic Surgeons. (2024). 2024 Plastic Surgery Statistics Report: Minimally Invasive Aesthetic Procedure Volumes Including Hyaluronic Acid Filler and Blunt-Tip Cannula Procedures. ASPS, 2024. plasticsurgery.org/news/plastic-surgery-statistics
• [5] Becton, Dickinson and Company. (2024). Q3 FY2024 Earnings Release: BD Nexiva Closed IV Catheter System Asia Pacific Distribution Expansion and IV Cannula Portfolio Performance. BD Investor Relations, August 2024. bd.com/en-us/company/investor-relations
• [6] Nipro Corporation. (2024). Annual Report 2024: Medical-Grade PVC IV Cannula Manufacturing Capacity Expansion in India and Government Tender Supply Program Participation. Nipro Investor Relations, 2024. nipro.co.jp/en/ir
• [7] Medtronic plc. (2024). FY2024 Annual Report: Cardiac Surgery Division Regulatory Submissions for Silicone-Body Cardiac Cannula Designs and Minimally Invasive Surgery Portfolio Update. Medtronic Investor Relations, June 2024. medtronic.com/en-us/about/investors.html
• [8] International Finance Corporation. (2024). Medical Plastics Supply Chain Review 2024: Medical-Grade PVC Pricing Trends, Petrochemical Feedstock Cost Pressures, and Impact on Single-Use Medical Device Manufacturing. IFC, 2024. ifc.org
• [9] Vygon Group. (2024). Product Innovation and Market Expansion Report 2024: Neonatal and Paediatric Micro-Bore IV Cannula Launch and Disposable Manufacturing Capacity Investment. Vygon Group, 2024. vygon.com
• [10] U.S. Centers for Medicare and Medicaid Services. (2024). Home Health and Oxygen Therapy Equipment Claims Data Report FY2024: Year-Over-Year Growth in Home Oxygen Therapy Equipment Including Nasal Cannula Supply Claims. CMS, 2024. cms.gov

This Report Addresses

• Strategic intelligence on cannula demand across IV access, oxygen therapy, surgical, aesthetic, and diagnostic applications for hospitals, clinics, ASCs, and home healthcare providers globally.
• Market forecast from USD 239.0 million in 2026 to USD 444.4 million by 2036, at a CAGR of 5.6%.
• Growth opportunity mapping across India PM-JAY procurement expansion, China hospital infrastructure growth, U.S. home healthcare oxygen therapy trends, and Brazil private hospital sector development.
• Segment analysis by product type (nasal, IV, cardiac, aesthetic), material type, application, end user, and usage type with leading sub-segment identification and share benchmarks.
• Regional outlook covering Asia Pacific hospital infrastructure demand, North America single-use compliance procurement, Europe EU MDR-driven conversion, and Latin America private healthcare expansion.
• Competitive landscape of Becton Dickinson, Teleflex, Medtronic, Smiths Medical, Vygon, Boston Scientific, Nipro, and ConvaTec covering product positioning, tender qualification status, and single-use portfolio strategies.
• Regulatory impact analysis covering FDA single-use device enforcement, EU MDR Article 17 reprocessing restrictions, India PM-JAY procurement guidelines, China NHC hospital expansion program, and Brazil ANVISA cannula registration requirements.
• Report delivered in PDF, Excel datasets, and presentation formats, supported by primary interviews, hospital tender data, regulatory clearance records, and procedural volume benchmarks.

Cannula Market Definition

The cannula market covers thin-walled tubes inserted into body cavities, veins, or ducts to deliver fluids, drugs, or gases, or to drain and monitor biological substances. These devices serve clinical applications spanning IV drug delivery, oxygen therapy, cardiac surgery, and aesthetic procedures.

Cannula Market Inclusions

Covers global and regional forecasts from 2026 to 2036. Includes nasal, IV, cardiac, aesthetic, and other cannula types. Segments by material, application, end user, and usage type. Covers hospital, clinic, ASC, and home healthcare procurement channels across disposable and reusable formats.

Cannula Market Exclusions

Excludes catheters and stents not classified as cannulas in clinical procurement. Omits intravenous infusion sets and blood transfusion systems sold as standalone assemblies. Also excludes endoscopy tubes and lumens classified under separate surgical instrument categories, focusing strictly on cannula devices and their immediate sterile supply.

Cannula Market Research Methodology

• Primary Research
  • Interviews with hospital procurement managers, surgical instrument distributors, infection control officers, and clinical device managers across the United States, Germany, India, China, Brazil, and Japan.
• Desk Research
  • Uses Becton Dickinson, Teleflex, and Medtronic public filings. Includes FDA 510(k) clearance records, CE marking registrations, hospital tender data, and infection control policy updates from 2024 to 2025.
• Market-Sizing and Forecasting
  • Hybrid top-down and bottom-up model. Based on unit shipment volumes, average selling prices by product type and material, and application-level procedural volume benchmarks segmented by end user and geography.
• Data Validation and Update Cycle
  • Validated against hospital procurement tender outcomes, regulatory clearance databases, and distributor earnings disclosures. Cross-checked with primary interviews and published clinical supply reports. Updated annually.